>>Signaling Pathways>> GPCR/G protein>> CCR>>ZK 756326 (hydrochloride)

ZK 756326 (hydrochloride)

Catalog No.GC45714

ZK 756326(염산염)은 CC 케모카인 수용체 CCR8에 대한 비펩티드 케모카인 수용체 작용제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

ZK 756326 (hydrochloride) Chemical Structure

Cas No.: 1780259-94-0

Size 가격 재고 수량
5mg
US$78.00
재고 있음
10mg
US$112.00
재고 있음
25mg
US$245.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ZK 756326 is a non-peptide agonist of the CC chemokine receptor CCR8. It inhibits binding of CCL1 to human CCR8 (IC50 = 1.8 μM) and induces Gai-mediated calcium-mobilization in U87 cells expressing the receptor.1 It exhibits greater than 28-fold selectivity for CCR8 over 26 other GPCRs but also binds to the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2B, 5-HT2C, and 5-HT5A with IC50 values of 5.4, 4.4, 34.8, and 16 μM, respectively. ZK 756326 stimulates extracellular acidification in cells expressing human and mouse CCR8 (EC50s = 254 nM and 2.6 μM, respectively). ZK 756326 induces ERK phosphorylation, exhibits leukocyte chemotactic activity, and inhibits HIV fusion of cells expressing CD4 and CCR8.

|1. Haskell, C.A., Horuk, R., Liang, M., et al. Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol. Pharmacol. 69(1), 309-316 (2005).

리뷰

Review for ZK 756326 (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ZK 756326 (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.